Myriam Curet sold $7.2M of ISRG
EVP & Chief Medical Officer at INTUITIVE SURGICAL INC. 13,466 shares at an average of $535.96, traded Nov 12, 2024, filed Nov 13, 2024.
Score components
- +15RoleOfficer
- +25Trade size$7.2M at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +0.5%, 3m +9.9%, 6m +5.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001035267-24-000265, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 12, 2024 | MOption exercise Common Stock10b5-1 | +2,257 | $177.99 | $402k | 2,555 | Nov 13, 2024 |
| Nov 12, 2024 | SOpen-market sale Common Stock10b5-1 | -2,257 | $535.96 | $1.2M | 298 | Nov 13, 2024 |
| Nov 12, 2024 | MOption exercise Common Stock10b5-1 | +5,000 | $182.83 | $914k | 5,298 | Nov 13, 2024 |
| Nov 12, 2024 | SOpen-market sale Common Stock10b5-1 | -5,000 | $535.96 | $2.7M | 298 | Nov 13, 2024 |
| Nov 12, 2024 | MOption exercise Common Stock10b5-1 | +2,199 | $229.39 | $504k | 2,497 | Nov 13, 2024 |
| Nov 12, 2024 | SOpen-market sale Common Stock10b5-1 | -2,199 | $535.96 | $1.2M | 298 | Nov 13, 2024 |
| Nov 12, 2024 | MOption exercise Common Stock10b5-1 | +4,010 | $208.90 | $838k | 4,308 | Nov 13, 2024 |
| Nov 12, 2024 | SOpen-market sale Common Stock10b5-1 | -4,010 | $535.96 | $2.1M | 298 | Nov 13, 2024 |
| Nov 12, 2024 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -2,257 | $0.00 | $0 | 0 | Nov 13, 2024 |
| Nov 12, 2024 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 0 | Nov 13, 2024 |
| Nov 12, 2024 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -4,010 | $0.00 | $0 | 2,005 | Nov 13, 2024 |
| Nov 12, 2024 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -2,199 | $0.00 | $0 | 2,829 | Nov 13, 2024 |
Related signals
Other insiders at INTUITIVE SURGICAL INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 24Weak | INTUITIVE SURGICAL INC | Fredrik Widman VP Corporate Controller | $408k 1,089 shares | -69% | |
| 3Weak | INTUITIVE SURGICAL INC | Mark Brosius EVP & Chief Mfg and Supply Cha | $17k 48 shares | -6% | |
| 3Weak | INTUITIVE SURGICAL INC | Mark Brosius EVP & Chief Mfg and Supply Cha | $25k 69 shares | -8% | |
| 15Weak | INTUITIVE SURGICAL INC | Myriam Curet EVP & Chief Medical Officer | $52k 105 shares | -100% | |
| 33Weak | INTUITIVE SURGICAL INC | Mark Brosius SVP & Chief Mfg and Supply Cha | $630k 1,293 shares | -44% | |
| 48Moderate | INTUITIVE SURGICAL INC | Mark Brosius SVP & Chief Mfg and Supply Cha | $1.8M 3,658 shares | -56% | |
| 33Weak | INTUITIVE SURGICAL INC | Myriam Curet EVP & Chief Medical Officer | $2.4M 4,853 shares | -92% | |
| 33Weak | INTUITIVE SURGICAL INC | Myriam Curet EVP & Chief Medical Officer | $1.2M 2,345 shares | -85% | |
| 21Weak | INTUITIVE SURGICAL INC | Myriam Curet EVP & Chief Medical Officer | $260k 526 shares | -56% | |
| 16Weak | INTUITIVE SURGICAL INC | Myriam Curet EVP & Chief Medical Officer | $66k 126 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.